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PL1: TARGETING K-RAS DRIVEN LUNG AND PANCREATIC TUMORS
MARIANO BARBACID
Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain 
(e-mail: mbarbacid@cnio.es)
K-RAS oncogenes have been implicated in about one fi fth of all human cancers including lung adeno-
carcinoma and pancreatic ductal adenocarcinoma, two tumor types with some of the worse prognosis. 
Unfortunately, in spite of intense research eff orts, identifi cation of suitable therapies to treat these tumors 
remains elusive. Indeed, patients suff ering from these tumor types are still treated with cytotoxic com-
pounds approved more than two decades ago. In order to identify novel and eff ective therapeutic strate-
gies, we have developed genetically engineered mouse (GEM) models that closely recapitulate their natu-
ral history. We are using these mice to validate targets of potential therapeutic value with the ultimate goal 
to translate these fi ndings to the clinic. In previous studies, we have crossed these GEM models with mice 
that carried either germ line or lox-Cre conditional knock out alleles encoding each of the downstream 
kinases of the Raf/Mek/Erk pathway as well as the cell cycle interphase Cdks to interrogate their role in the 
development of K-Ras driven lung adenocarcinomas. These studies have led us to validate the c-Raf, 
Mek1/2, Erk1/2 and Cdk4 kinases as critical targets for these tumors (Puyol et al., Cancer Cell 2010; Blasco 
et al., Cancer Cell 2011). Following a similar strategy, we have also demonstrated that the EGF Receptor 
and c-Raf are required for the development of PanIN lesions, a precursor for the formation of K-Ras driven 
pancreatic ductal adenocarcinomas (Navas et al., Cancer Cell 2012). Moreover, we have established that 
whereas systemic ablation of the Mek1/2 and Erk1/2 kinases result in the rapid death of the animals, mice 
tolerate reasonably well the systemic elimination of c-Raf, Cdk4 and EGF Receptors. Hence, making these 
kinases suitable targets for K-Ras driven lung and pancreatic tumors. 
More recently, we have decided to interrogate the role of these targets in advanced tumors. To this 
end, we have generated new GEM models in which expression of the resident K-Ras oncogene, as well as 
ablation of the p53 tumor suppressor is mediated by the frt-FLp(o) targeting system, a strategy that allows 
us the temporal and spatial separation of tumor development from target ablation. In addition, we have 
generated lox-Cre based conditional knock-in strains for c-Raf, Cdk4 ERF Receptors and PI3K p110α that, 
upon recombination, direct the expression of kinase dead isoforms instead of inducing protein ablation. 
We feel that these strains should serve as bett er models to mimic drug intervention in the clinic. Whereas 
inactivation of some of these kinases (Cdk4 and EGF Receptor) leads to results comparable to those 
obtained by ablating protein expression, in the case of c-Raf, the results appear to be signifi cantly diff erent. 
Finally, we are now combining the ablation and/or inactivation of these targets in K-Ras/p53 mutant lung 
and pancreatic GEM tumors in order to identify therapeutic combinations that may eventually eradicate 
these advanced tumors. We hope that these studies will serve to guide the design of future clinical trails to 
treat patients carrying K-RAS mutant tumors.
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PL2: STROMAL CELL ACTIVATION IN PRIMARY 
AND METASTATIC BREAST CANCER
CLARE ISACKE
The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom 
(e-mail: Clare.Isacke@icr.ac.uk)
The interaction of tumour cells with stroma cells and stromal components not only promotes tumour 
progression and metastasis, but also infl uences tumour cell responses to chemotherapy, endocrine ther-
apy and targeted agents. As a consequence, there is an urgent need to identify strategies to effi  ciently tar-
get these interaction pathways for the prevention or suppression of metastatic disease and to overcome 
treatment-resistant tumour progression in advanced breast cancer. 
We are interrogating the tumour-stroma crosstalk pathways underpinning the striking heterogeneity 
between diff erent breast cancers in their ability to recruit and activate a pro-tumorigenic stroma. These 
studies are focussed on (a) the mechanisms involved in the activation of cancer-associated fi broblasts 
(CAFs) and the diff erent functional roles played by activated and non-activated CAFs, (b) the role of acti-
vated pericytes in promoting metastatic dissemination, and (c) the mechanisms by which a productive 
microenvironmental niche is initiated at metastatic sites.
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K: EMERGENCE OF PHENOTYPES IN AGING AND DISEASE
MIROSLAV RADMAN1,2
1 Mediterranean Institute for Life Sciences (MedILS), Split, Croatia 
2 Inserm U-1001, Université Paris-Descartes, Faculté de Médecine Paris-Descartes, Paris, France 
(e-mail: miroslav.radman@gmail.com)
This talk is about concepts rather than mechanisms. Aging and age-related diseases will be consid-
ered as emerging phenotypes of increasingly damaged progressively malfunctioning proteomes. Similar-
ity between disease and mortality rates hints to a common cause underlying aging and age-related dis-
eases, called intrinsic aging. From our comparative studies of robust and standard species, dysfunctional 
oxidatively damaged proteins appear as the likely root cause of radiation-induced and age-related mor-
bidity and mortality with snowballing phenotypic consequences (Radman, DNA Repair 2016; Krisko and 
Radman, PLoS Genetics 2013). I shall elaborate: (i) how protein polymorphism translates to damage poly-
morphism that can determine the predisposition to age-related diseases, (ii) how proteome damage pro-
duces phenotypes, either directly or indirectly via generation of mutations (Radman and Radman, PLoS 
Genetics 2013) and acceleration of their phenotypic expression, and (iii) the perspectives for diagnosis, 
prognosis, prevention and cure of degenerative diseases.
Libri Oncol., Vol. 44 (2016), No 1, 3–25
8
L1: TRACING THE EVOLUTIONARY ORIGIN OF TUMORS
TOMISLAV DOMAZET-LOŠO1,2
1 Laboratory of Evolutionary Genetics, Division of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia 
2 Catholic University of Croatia, Zagreb, Croatia 
(e-mail: tdomazet@irb.hr)
Molecular nature of malignant tumors is well studied in vertebrates, while their evolutionary origin 
remains to be uncovered. In particular, there is no evidence for cancers in pre-bilaterian animals, although 
recent computational studies have predicted that all metazoans are prone to develop tumors. We provide 
the fi rst evidence for naturally occurring tumors in the cnidarian genus Hydra. Histological, cellular and 
molecular data reveal that these tumors are transplantable, caused by diff erentiation arrest of female gam-
etes, and their growth is independent on the cellular environment. Tumor bearing polyps have signifi -
cantly reduced fi tness as evidenced by their clonal growth retardation and reduced fecundity. In addition, 
the Hydra tumors show a greatly disturbed transcriptome that mimics expression shifts in vertebrate 
cancers. Therefore, this shows that invasive tumors have deep roots in animal phylogeny, and that simple 
animals may be informative in revealing the fundamental mechanisms of tumorigenesis.
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L2: THE METASTASIS SUPPRESSOR GENE FAMILY Nme/Nm23/NDPK: 
LESSONS FROM MODEL ORGANISMS
MAJA HERAK BOSNAR1, DRAGO PERINA2, MATIJA HARCET2, ANDREJA MIKOČ2, 
RUŽICA BAGO1, MARTINA DEŽELJIN1, HELENA ĆETKOVIĆ2
1 Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia 
(e-mail: mherak@irb.hr) 
2 Laboratory for Molecular Genetics, Division of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia
The Nme gene/protein family, initially called nucleoside diphosphate kinase (Nm23/NDPK), consists 
of evolutionarily conserved genes/proteins present in all three domains of life. This family of proteins was 
originally named after the fi rst member identifi ed, Nm23-H1/Nme1, which is responsible for metastasis 
suppression of many tumor types. The Nme1/NDPKA and Nme2/NDPKB are two units of a well-known 
enzyme nucleoside-diphosphate kinase (NDPK), which transfers the terminal phosphate form (d)NTPs to 
(d)NDPs and is, therefore, responsible for the maintenance of the cellular nucleotide pool. Besides this 
housekeeping role, the Nme/NDPK proteins have been assigned several additional biochemical functions. 
Numerous proteins from evolutionary distinct organisms exhibit extraordinary similarity in their struc-
tures with their orthologs in mammals including humans. Therefore, it is presumed that they have similar 
or identical biochemical and biological functions. The goal of our studies was to determine the structure, 
function and evolution of several members of the Nme/NDPK family in model systems evolutionary very 
distinct form humans. Our studies were focused on nme homologs/orthologs in ‘non-bilaterian’ Metazoa, 
namely sponges (Porifera). Sponges are simple animals and are considered to be the closest to the common 
metazoan ancestor. Series of biochemical and biological tests, especially the formation of stable clones 
expressing the sponge variant of the Group I Nme gene which inhibited the migratory potential of human 
tumor cells, implied that its function in migration processes was engaged before the origin of true tissues, 
and genesis of tumors and metastasis. This suggests that the common ancestor of Metazoa possessed a 
functional NmeGp1 metastatic suppressor gene/protein homolog and that several of its multiple functions 
existed before the emergence of true multicellularity. Recently we have done a similar study on the Nme 
homolog from a unicellular fi lasterean organism Capsaspora owczarzaki, which was also able to suppress 
migration potential of human cells although the human, sponge and fi lasterean proteins exhibit some 
structural diff erences.
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L3: ONCOGENIC p63 SIGNALLING IN MELANOMA AND ITS LINK 
WITH ACQUIRED RESISTANCE TO MAPK INHIBITORS
 ANKIT PATEL, CATHERINE A. HARWOOD, DANIELE BERGAMASCHI
Centre for Cell Biology and Cutaneous Research Blizard Institute, Barts and The London SMD, QMUL, London, 
United Kingdom 
(e-mail: d.bergamaschi@qmul.ac.uk) 
Targeted therapy with specifi c BRAF inhibitors (BRAFi) has improved both overall and progression-
free survival in melanoma. Despite impressive initial responses, most patients eventually relapse due to 
pre-existing or acquired BRAFi resistance. Several mechanisms have been linked to this acquisition of 
resistance, including NRAS and MEK1 mutations, increased expression of MAP3K, Cot1, cyclin D1 and 
growth factor receptors. However, the signaling pathways involved in acquired BRAFi resistance in mela-
noma are not yet fully understood, placing limitations on successful development of second-line treat-
ments which are urgently needed for patients resistant to BRAFi. We have recently provided the fi rst evi-
dence of signifi cant p63 expression in melanoma cell lines and clinical samples and demonstrated its link 
with poor prognosis. We identifi ed a p63 location/expression patt ern in melanoma cells, which diff ers 
from that previously reported in cells of keratinocyte lineage or in cutaneous SCC. We have also reported 
how p63 inhibits p53 apoptotic function in melanoma cells exposed to genotoxic drugs. We have now 
identifi ed a signifi cant correlation between p63 expression and mutational status of BRAF/NRAS in clini-
cal samples, reinforcing the link between p63 expression and activation of the MAPK signalling pathway 
in melanoma. In addition, we have established cellular models of melanoma BRAFi resistance that display 
increased expression of p63 isoforms at both mRNA and protein levels. Further analysis of several p63 
interacting proteins in melanoma cells chronically exposed to BRAFi reveals a novel signalling pathway 
involved in the development of resistance and suggests that strategies aimed at reducing endogenous p63 
levels in metastatic melanoma may provide a therapeutic approach to counteract BRAFi resistance-associ-
ated MAPK pathway activation.
11
Libri Oncol., Vol. 44 (2016), No 1, 3–25
L4: TARGETING HEDGEHOG-GLI SIGNALING IN CANCER: 
NEW CONCEPTS AND STRATEGIES
FRITZ ABERGER
Cancer Cluster Salzburg, Department of Molecular Biology, Paris-Lodron University of Salzburg, Salzburg, Austria 
(e-mail: Fritz .Aberger@sbg.ac.at)
Uncontrolled Hedgehog (HH) signaling leads to initiation and progression of numerous cancer enti-
ties and therefore constitutes a promising target for cancer therapy. Clinically advanced inhibitors of the 
HH pathway targeting the essential HH eff ector Smoothened (SMO) are promising therapeutic drugs. 
However, development of drug resistance, SMO-independent GLI pathway activation and severe side 
eff ects limit the application of these SMO modulators, urgently calling for novel and improved therapeutic 
strategies.
The oncogenicity of the HH/GLI cascade is also regulated by non-canonical, Smoothened-indepen-
dent mechanisms by integration of common oncogenic driver signals. Identifying synergistic pathway 
interactions may therefore guide the way to new therapeutic opportunities based on rational combination 
treatments. The presentation will summarize eff orts to identify cooperative pathway interactions of HH/
GLI signaling in cancer as well as discuss new data on kinases and potential drug targets that positively 
regulate oncogenic GLI transcription factors.
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L5: GENETICS AND EPIGENETIC ALTERATIONS OF HEDGEHOG-GLI 
SIGNALING PATHWAY IN OVARIAN TUMORS
SONJA LEVANAT
Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia 
(e-mail: levanat@irb.hr)
Hedgehog-Gli (Hh-Gli) signaling pathway is the essential for tissue development and stemness, and 
its deregulation has been observed in many tumors. Its aberrant activation as a result of genetic and epi-
genetic alterations has been reported in various types of tumors.
Our research showed Hh-Gli pathway to be active in ovarian tumors, both carcinoma and borderline 
tumors, and GLI1 and SUFU expression was associated with tumor type and FIGO grade. Point mutations 
of the main members of Hh-Gli pathway were not detected in any type of investigated ovarian tumors, but 
some of PTCH1 polymorphisms were signifi cantly less frequent in both benign and malign ovarian tumors 
compared to healthy controls. In addition, loss of the entire PTCH1 gene has been observed in ovarian 
dermoids, ovarian fi broma and ovarian carcinoma.
Epigenetic alterations of Hh-Gli pathway genes in the development of various ovarian tumors have 
mostly been reported as a promoter hypermethylation of tumor suppressor gene PTCH1. We have shown 
that in benign ovarian tumors the PTCH1 promoter was mostly methylated in the CpG island located near 
the GLI-binding site, thus preventing the PTCH1 expression and obstructing the pathway negative feed-
back loop in which GLI1 stimulates the expression of PTCH1. On the contrary, it seems that PTCH1 pro-
moter methylation is not present in ovarian cancer. By whole-genome DNA methylation profi ling of ovar-
ian cancer, others found two additional Hh-Gli pathway members, ZIC1 and ZIC4, to be silenced by 
hypermethylation, what was correlated with increased proliferation, migration and invasion (Huang et al., 
Epigenetics 2013). An alternative epigenetic modifi cation of Hh-Gli pathway is possible through the inhi-
bition of BET bromodomain proteins: RD4 regulates GLI1 and GLI2 transcription occupying their promo-
tors (Tang et al., Nat Med 2014).
We recently started to investigate the role of microRNA in ovarian cancer etiology driven by deregu-
lation of Hh-Gli signaling pathway. We hypothesize that their expression profi le can be more accurately 
correlated with cell diff erentiation and developmental status compared to mRNA profi le. Our fi rst results 
highlighted more than dozen candidate microRNAs potentially targeting Hh-Gli signaling pathway genes, 
which have to be additionally verifi ed and investigated.
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L6: MULTI-SYSTEM ANALYSIS OF GENOME-WIDE MUTATIONAL 
SIGNATURES: IMPLICATIONS FOR MOLECULAR CANCER EPIDEMIOLOGY
JIŘÍ ZAVADIL
Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer (IARC), 
World Health Organization (WHO), Lyon, France 
(e-mail: zavadilj@iarc.fr)
Mutational spectra in cancer genomes have the potential to reveal past carcinogenic exposures and 
can thus point to the causal events underlying the onset and evolution of cancer. Consequently, genome-
wide analyses of mutational signatures, carried out in the context of molecular cancer epidemiology stud-
ies, can inform hypotheses on particular etiological factors for specifi c cancer types. Owing to the advances 
in massively parallel sequencing technologies and associated bioinformatics methods, data on mutation 
landscapes in human primary tumors accumulate exponentially. However, there remains a need for com-
plementary experimental studies allowing further characterizing of mutagenic insults associated with 
particular candidate carcinogens. Innovative multi-system approaches using robust cell-based and animal 
models will be presented, with a focus on their potential for deep investigations of exposure-specifi c 
impact on the genome, their capacity to accelerate the identifi cation of cancer-specifi c etiological factors, 
and ultimately on their promising role in systematic carcinogen evaluation, classifi cation, and in cancer 
prevention measures.
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L7: RECENT ADVANCES IN CANCER IMMUNOTHERAPY
ZLATKO DEMBIĆ
Department of Oral Biology, Dental Faculty, University of Oslo, Oslo, Norway 
(e-mail: zlatko.dembic@odont.uio.no)
By being successful in advanced stages of several solid tumors, novel treatments using modifi cations 
of patients’ immune system have changed the current models of oncologic therapy. Collectively named 
oncologic immunotherapy, they show promise to change the therapeutic regimens in many malignancies 
in the future. The recent increase in clinical trials with immunotherapy has been encouraged with the suc-
cess of the use of immune checkpoint inhibitors. These follow previous trials using chimeric antigen recep-
tor modifi cation, various tumor-antigen “specifi c” vaccines and viral vectors to combat cancer. The immu-
notherapeutic “arsenal” can boost, empower or tailor patient’s own immune system to seek and kill can-
cerous cells throughout the body. Therapies like immune checkpoint inhibition (anti-PD1, anti-CTLA4) in 
melanoma, non-small-cell lung cancer and renal cancer, peptide vaccination in prostate cancer and glio-
blastoma, and oncolytic immunotherapy in melanoma have been approved by regulatory authorities and 
are already in clinical use. Ongoing clinical trials are currently pursuing novel therapeutic sett ings and 
treatment combination for appropriate patient populations trying to maximize benefi ts of immunothera-
peutic regimens. There is a search to fi nd biomarkers that could be used for continuous monitoring of 
treatments’ successes and identifi cation of therapeutic targets. These biomarkers will be important for the 
ideal implementation of immunotherapy into cancer therapies of the future. Some biomarkers might 
belong to a group of hereditary risk factors for cancer, which could be essential for early diagnostics and 
prognosis. Our recent search for genetic risk factors in various types of solid tumors will be discussed.
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L8: EXTRACELLULAR VESICLES AND THEIR THERAPEUTIC POTENTIAL
AGNES KITTEL1, XABIER OSTEIKOETXEA2, KATALIN SZABÓ-TAYLOR2, 
TAMÁS GÉZA SZABÓ2, EDIT IRÉN BUZÁS2
1 Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Science, Budapest, 
Hungary 
(e-mail: kitt el.agnes@koki.mta.hu) 
2 Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary
The story of extracellular vesicles (EVs), these cell-secreted phospholipid bilayer-bound structures 
started about 70 years ago. The release of membrane vesicles is a process conserved in both prokaryotes 
and eukaryotes and compelling piles of evidence support the signifi cance of exosomes, microparticles/
microvesicles (MV/MP) and apoptotic bodies in a broad range of physiological-pathological conditions. 
EVs derived from cancer cells have been shown to contribute to horizontal cellular transformation, 
cellular reprogramming, functional alterations, even metastasis. Besides that identifi cation of the tumour-
derived material carried by EVs isolated from diff erent body fl uids can help the early detection of diff erent 
cancers, the more accurate diagnosis and prognosis today, and these small vesicles might become effi  cient 
therapeutic tool in the future.
The main goal of the talk is to convince you about the existence, importance and therapeutic potential 
of extracellular vesicles, as well as to give an insight into the diffi  culties of their isolation and identifi cation.
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L9: PRECISION MEDICINE IN MYELOID LEUKEMIA: 
PREDICTIVE PHARMACOGENOMICS BIOMARKERS 
OF DRUG SENSITIVITY AND RESISTANCE
KARMEN STANKOV
Clinical Center of Vojvodina, Medical Faculty of Novi Sad, University of Novi Sad, Novi Sad, Serbia 
(e-mail: stankov_karmen@uns.ac.rs)
Myeloid leukemia represents a highly variable and heterogeneous disease on the basis of clinical 
course and molecular indicators. Precision medicine in myeloid leukemia is required in frontline induc-
tion and post-remission consolidation therapy, as well as in salvage post-relapse therapy. Personalized 
approach enables the identifi cation and use of pharmacogenomics biomarkers selected from comprehen-
sive landscape of genetic alterations. Due to technical advancements, molecular diagnostics and response 
monitoring are applied in eff ective and molecularly targeted therapy. Detailed insight into the genetic and 
epigenetic biomarkers of the disease is implemented in leukemia classifi cation and pretreatment risk-cat-
egorization. In addition to clinical and molecular response parameters, biomarker-guided targeted molec-
ular therapy response represents the most sensitive evaluation approach and prognostic system. It is 
applied to distinguish the complete, suboptimal and lack of response, indicating the need for change of 
treatment or bone-marrow transplantation. Biomarkers of targeted response are successfully applied in 
elucidation and detection of molecular mechanisms of primary/secondary resistance development in 
order to initiate adequate treatment for drug-resistant cases in a timely manner. With medical progress, 
application of pharmacogenomics biomarkers in myeloid malignancies is crucial to eff ectively predict 
drug sensitivity/resistance and to eff ectively guide treatment decisions. The goal of this talk is to summa-
rize the latest advancements in precision medicine in myeloid leukemia with particular emphasis on eval-
uation and application of predictive pharmacogenomics biomarkers of drug sensitivity and resistance.
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L10: CELL COMPOSITION IN p53 ISOFORMS DEFINES CELL FATE DECISION
SEBASTIEN JORUIZ, ALEXANDRA DIOT, SYLVANIE SURGET, VALERIE MEURAY, SOPHIE ADAMS, 
EVA VOSIKA, KENNETH FERNANDES, JEAN-CHRISTOPHE BOURDON
University of Dundee, Medical School, Dundee Cancer Centre, Dundee, United Kingdom 
(e-mail: j.bourdon@dundee.ac.uk)
All genetic models, experimental and clinical data indicate that TP53 gene play key roles in cancer 
formation, progression and treatment. For 30 years, it was thought that TP53 is a dedicated tumor-sup-
pressor encoding a single transcription factor, p53, which protects cells from genotoxic stress. However, it 
is poorly understood how a single protein, p53, can be responsive to so many stress signals and orches-
trates very diverse cell responses to maintain/restore cell/tissue functions. 
The uncovering that TP53 gene physiologically expresses, in a tissue-dependent manner, not one p53 
protein but twelves diff erent p53 proteins with distinct biochemical activities (p53 isoforms) may prove 
fundamental to decipher the p53 pathway and improve cancer treatment. Over the last decade, all genetic 
animal models of p53 isoforms (zebrafi sh, drosophila and mouse), have consistently indicated that alter-
ing expression of a few p53 isoform, without aff ecting canonical p53 protein expression (i.e. p53alpha), 
promote diff erent pathologies: premature ageing, (neuro)degenerative diseases, infl ammation, cancer, 
embryo malformation and altered responses to ionising irradiation or infectious diseases. The p53 iso-
forms are dynamically reforming in depth the p53 fi eld. 
I will summarise a decade of research on p53 isoforms and present our latest experimental and clini-
cal studies in breast cancer that could be extended to predict response to treatment in other type of cancer.
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ST1: THE EXPRESSION OF p53/p73 ISOFORMS, NME AND GLI 
IN METASTATIC MELANOMA AND THEIR INDUCTION BY γ-IRRADIATION
NIKOLINA HANŽIĆ1, BASTIEN PROUST1, LIDIJA PETROVIĆ1, PETAR OZRETIĆ2, IVAN MILAS3, 
MAJA HERAK BOSNAR1, SONJA LEVANAT2, NEDA SLADE1
1 Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia 
(e-mail: nhanzic@irb.hr) 
2 Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia 
3 Department for Oncoplastic and Reconstructive Surgery, University Hospital for Tumors, University Hospital 
Center Sestre milosrdnice, Zagreb, Croatia
Although mutations of p53 occur infrequently in melanoma, it fails to function as a tumor suppressor. 
This may result from alterations in p53 family members, including the diverse isoforms of p53 and its 
homologue p73. Moreover, we assume that the p53 function in malignant melanoma might be altered 
through interactions with p53 small molecular weight and p73 isoforms, NME and GLI families of pro-
teins. Therefore, we are studying the expression profi le of p53 and its potential interaction partners (p73/
NME/GLI) in metastatic melanoma and in adjacent healthy skin tissue. In the study on 30 patients with 
metastatic melanoma, the expression of p53, p73, NME and GLI protein families was determined by west-
ern blot analysis and quantitative RT-PCR. 
Protein expression analysis has shown that only Δ133p53α expression is signifi cantly diff erent in the 
two tissue types: it is poorly expressed in healthy tissue (only 12% of samples), but strongly expressed in 
tumor tissue (72% of samples). There is no diff erence of expression of other p53 isoforms between healthy 
and tumor tissue samples. Protein p73 is expressed in almost all tumor samples and healthy tissue sam-
ples. TAp73α and ΔNp73α, are more frequent in tumor samples and TAp73 β and ΔNp73 β, are less fre-
quent in tumor samples than in healthy tissue samples. Proteins NME1 and NME3 are expressed in 96% 
of tumor samples and 70% of healthy tissue samples. Surprisingly, protein expression of NME1 and NME2 
was several fold higher in tumor samples than in healthy tissue samples. GLI1 and both GLI3A and GLI3R 
have higher expression in tumor than in healthy tissue samples. GLI2 is expressed in only 8% of tumors 
and not in healthy tissue samples. 
Comparison of gene expression in the melanoma tissue samples and corresponding normal tissue 
revealed that NME2 is signifi cantly stronger expressed in normal tissue while NME1 is expressed equally 
in healthy and tumor tissue. All other examined genes are signifi cantly less expressed in the tumor tissue.
To obtain higher expression of proteins of interest, we irradiated two melanoma cell lines with diff er-
ent mutational status of p53 (Mel505/p53mut and A375M/p53wt) with γ rays with the dose of 5 and 10 Gy. 
The results have shown that γ irradiation increases the level of proteins of interest to certain extent and 
their protein expression profi les obtained after γ irradiation provide the molecular environment where the 
proteins possibly interact and inhibit activity of p53 in melanoma.
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ST2: INTERACTION OF THE HUMAN PAPILLOMAVIRUS E6 ONCOPROTEIN 
WITH SORTING NEXIN 27 MODULATES ENDOCYTIC CARGO TRANSPORT 
PATHWAYS
VJEKOSLAV TOMAIĆ1,2
1 Tumor Virology Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy 
2 Laboratory of Molecular Virology and Bacteriology, Division of Molecular Medicine, Ruđer Bošković Institute, 
Zagreb, Croatia 
(e-mail: tomaic@irb.hr)
A subset of high-risk Human Papillomaviruses (HPVs) are the causative agents of a large number of 
human cancers, of which cervical is the most common. Two viral oncoproteins, E6 and E7, contribute 
directly towards the development and maintenance of malignancy. A characteristic feature of the E6 onco-
proteins from cancer-causing HPV types is the presence of a PDZ binding motif (PBM) at its C-terminus, 
which confers interaction with cellular proteins harbouring PDZ domains. Here we show that this motif 
allows E6 interaction with Sorting Nexin 27 (SNX27), an essential component of endosomal recycling 
pathways. This interaction is highly conserved across E6 proteins from multiple high-risk HPV types and 
is mediated by a classical PBM-PDZ interaction but unlike many E6 targets, SNX27 is not targeted for 
degradation by E6. Rather, in HPV-18 positive cell lines the association of SNX27 with components of the 
retromer complex and the endocytic transport machinery is altered in an E6 PBM-dependent manner. 
Analysis of a SNX27 cargo, the glucose transporter GLUT1, reveals an E6-dependent maintenance of 
GLUT1 expression and alteration in its association with components of the endocytic transport machinery. 
Furthermore, knockdown of E6 in HPV-18 positive cervical cancer cells phenocopies the loss of SNX27, 
both in terms of GLUT1 expression levels and its vesicular localization, with a concomitant marked reduc-
tion in glucose uptake, whilst loss of SNX27 results in slower cell proliferation in low nutrient conditions. 
These results demonstrate that E6 interaction with SNX27 can alter the recycling of cargo molecules, one 
consequence of which is modulation of nutrient availability in HPV transformed tumour cells.
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ST3: IDENTIFICATION OF NOVEL GENES RESPONSIBLE 
FOR CHEMORESISTANCE IN BREAST CANCER
FEDERICA ALESSANDRINI, LAURA PEZZE’, YARI CIRIBILLI
Laboratory of Molecular Cancer Genetics (LMCG), Centre for Integrative Biology (CIBIO), University of Trento, 
Trento, Italy 
(e-mail: yari.ciribilli@unitn.it)
Tumor microenvironment (TME) plays a critical role in cancer progression and response to therapies. 
Cancer therapeutic intervention strategies can induce infl ammation, resulting in changes in the TME. To 
investigate the response of cancer cells to chemotherapy in the context of an infl ammatory microenviron-
ment, we studied the eff ects driven by the chemotherapeutic drug doxorubicin (D), and the infl ammatory 
cytokine TNFα (Τ).
We previously demonstrated using expression microarrays (validated also through qPCR) that the 
D+T combined treatment determined a strong up-regulation of migration-related genes as well as increased 
motility in breast cancer cells (MCF7). 
We confi rmed the synergistic activation of a group of 6 diff erent genes upon D+T combined treatment 
in diff erent cancer cell line models (A549-lung, U2OS-bone). Moreover, we demonstrated that the eff ect 
was only partially p53-depenedent but strongly doxorubicin-dependent using p53 mutated MDA-MB-231 
breast cancer cells or knocking-out wild-type p53 in MCF7 or U2OS cells through the cutt ing edge technol-
ogy CRISPR/Cas9.
We also demonstrated that the combined D+T treatment was not only able to disrupt the 3D architec-
ture of mammary acini observed with MCF10A primary cells, but also to stimulate the tube-forming 
potential of Human Umbilical Vein Endothelial Cells (HUVEC).
Furthermore, a signature of D+T highly synergistic genes (DT-29) was shown to exhibit prognostic 
value for luminal breast cancer patients, with adverse outcome correlating with higher relative expression 
(based on Kaplan-Meier plott er tool).
Since STAT3 pathway is often activated in response to cancer-related infl ammation, we demonstrated 
a STAT3-dependent regulation for some of the selected genes and STAT3 inhibition resulted also in a 
reduced migration potential of cancer cells. 
Among the group of up-regulated genes upon D+T, we identifi ed ETV7 and LAMP3 as putative medi-
ator of the increased migratory potential of cancer cells. ETV7 is a member of the large family of ETS tran-
scription factors that usually acts as transcriptional repressor; LAMP3 is a lysosome-associated membrane 
protein reported to be important for autophagy-dependent cell migration. Interestingly, we have recently 
proved that over-expression of ETV7 and LAMP3 was able to stimulate the migration potential of breast 
cancer cells. 
In summary, we have identifi ed pathways and genes whose activation can be related to breast cancer 
chemoresistance and aggressiveness.
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Although thyroid cancer comprises only about 2% of new cancer cases, it is one of the fastest-growing 
cancer types, according to GLOBOCAN2012. Incidence of thyroid cancer in Croatian population is among 
the highest in Europe. At the same time it is more frequent in female population (4-fold compared to male 
population) and is most usually detected at ages 50-59. 
We performed a case-control study of 100 untreated patients with thyroid diseases (papillary thyroid 
cancer, follicular thyroid adenoma, etc.) and 100 controls. The case population refl ected the characteristics 
of a global population with thyroid cancer in mean group age 52.23±13.21 years and 4:1 female:male ratio. 
The control population was matched in age, gender, and smoking status to minimize the infl uence of con-
founding factors.
Among the patients, the average plasma-protein carbonyl concentrations were higher 1.26-fold, but 
the catalase activity was lower 35% compared to control population. With regard to cytogenetic parame-
ters, higher total number of chromosome aberrations (1.47-fold), comet assay tail moment (2.25-fold) and 
total numbers of micronuclei (2.32-fold), nuclear buds (2.34-fold), and nucleoplasmic bridges (3.98-fold) 
were detected in the case group. About 98% of patients were positive for either B-Raf or Ret protein expres-
sion in thyroid tissue. Papillary thyroid cancer patients expressed B-Raf protein more frequently (97.06%) 
than did the patients with follicular thyroid adenoma (78.38%) or other thyroid diseases (79.17%). 
We have observed altered oxidative and cytogenetic status of patients with thyroid diseases, sup-
ported by changes in protein expression and localisation. We hope that such data could be used for iden-
tifi cation of subgroups at increased risk.
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B-cell chronic lymphocytic leukaemia (B-CLL) is the most common blood cancer in adults. The dis-
ease is characterized by progressive accumulation of mature monoclonal but functionally incompetent 
lymphocytes in blood, bone marrow, lymph nodes and spleen/liver that co-express the CD5 antigen and 
B-cell antigens CD19, CD20 and CD23. The presence of the aberrant B-cell clone (CD5+CD19+) greatly 
facilitates the disease diagnostics as well as the characterization of individual cell groups within the sam-
ple. This clone is essentially an uncontrollably multiplied precursor of mature B-cells which makes CLL a 
model for studying the development and diff erentiation of B-cells. The eff ects of the Notch signalling 
pathway in the immune system have been shown to aff ect hematopoietic stem cells, as well as committ ed 
progenitors. By guiding the specifi cation, maturation and survival of progenitors it eff ectively moulds the 
immune compartments and shapes the faith of hematopoietic cells. The role in promoting survival and 
apoptosis resistance of Notch signalling has been thoroughly explored in T-cell acute lymphoblastic leu-
kaemia but the conclusions of the work done with this specifi c pathway in B-CLL have been contradictory. 
B-CLL cells are characterized by in vivo resistance to apoptosis which remains a major clinical challenge 
for successful treatment of the disease. It has been shown that Notch 1 is being mutated in 12% cases of 
B-CLL and it has been also implied that Notch 1 mutations are predictors of poor prognosis. However, the 
relationship between the genetic aberrations and drug resistance or disease progression remains unclear. 
In addition to Notch, we have turned our att ention towards other modulators of lymphocyte diff erentia-
tion, such as Aiolos and other members of the Ikaros family zinc -fi nger proteins. These transcription fac-
tors modify the expression of genes by binding and remodelling chromatin thus regulating the activity in 
the nucleus and guiding the lineage specifi cation of B cells. We and others have shown that Ikaros family 
member, Aiolos is highly expressed in B-CLL cells and there is evidence supporting their role in survival 
of mature neoplastic B-cells. The expression of the downstream genes was assessed by gene expression 
assays and multiplex PCR. In this work we have made some promising steps towards elucidating the 
intricate mechanism of B cell lineage specifi cation and the genes involved in guiding it.
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Breast cancer is the most commonly diagnosed cancer in female population worldwide and it is esti-
mated that approximately one out of every eight Croatian women will develop invasive breast cancer over 
the course of her lifetime. Advances in understanding tumor biology, particularly signaling pathways, 
have led to the development and approval of many novel agents and have changed the landscape of 
therapy for patients with metastatic breast cancer. However, metastatic breast cancer still remains an 
incurable disease for most patients. The most important future strategies will be those for overcoming 
endocrine and human epidermal growth factor 2-neu (HER2) resistance, targeting triple-negative breast 
cancers through novel receptors, harnessing the immune system, and new ways of targeting angiogenesis. 
Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast cancers and has 
an important role in tumor growth and progression. Endocrine therapy forms the backbone of treatment 
for hormone-dependent breast cancer. Despite the benefi ts of endocrine therapy, resistance eventually 
occurs in a large number of patients and represents important clinical challenge in the management of 
breast cancer. Understanding the mechanisms of resistance to endocrine therapies which have been identi-
fi ed helps us develop novel potential drugs to overcome resistance. A new strategy in treating patients 
with ER-positive breast cancer is to target cyclin-dependent kinases 4 and 6 (CDK4/6), a key pathway 
involved in regulation of the G1/S transition of the cell cycle. 
Cancers over-expressing a protein receptor HER2 (HER2 IHC 3+, or FISH-positive) may be treated 
with targeted therapies such as trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine. 
Despite the important treatment advances with these potent anti-HER2 therapies, these drugs are  generally 
not curative in the metastatic sett ing, likely due to several mechanisms of anti-HER2 therapy resistance.
Triple-negative breast cancer tends to have an aggressive phenotype with higher recurrence rates and 
lower survival rates. To date, there are no approved targeted therapies specifi cally for this subtype; how-
ever, many are in development. Ongoing research is investigating targetable novel cell surface receptors, 
the use checkpoint inhibitors, and identifying subgroups likely to benefi t from platinum-based therapies 
and poly(adenosine diphosphate-ribose) polymerase inhibitors. The androgen receptor (AR) has been 
identifi ed as a possible predictive biomarker for antiandrogen therapy in ER- breast cancer.
While numerous studies investigating anti–vascular endothelial growth factor (VEGF) therapy in the 
neoadjuvant sett ing suggest improved pathologic complete response rates, especially in TNBC, studies to 
date have not demonstrated a survival benefi t in the adjuvant sett ing or metastatic sett ing.
A promising fi eld of clinical research in breast cancer is the use of immune checkpoint inhibitors. By 
blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are 
designed to enhance pre-existing anti-cancer immune responses. Several studies investigating checkpoint 
inhibitors are currently enrolling breast cancer patients. Approximately 20% of TNBCs express PD-L1, and 
expression of PD-L1 is associated with poor prognosis, thus making this aggressive phenotype att ractive 
subtype in which to investigate PD-L1 blockade.
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Vitamin C has been known as a reducing agent with a number of biological functions (Du et al., Bio-
chim Biophys Acta 2012). On another side, compounds with a 1,2,3-triazole fragment have shown antipro-
liferative activities against a variety of cancer cell lines (Kraljević et al., Eur J Med Chem 2016). Design of a 
library of novel hybrid compounds of vitamin C and 1,2,3-triazole with various physicochemical charac-
teristics (such as lipophilicity and solubility) and antioxidant capacity, through interdisciplinary approach 
will be outlined. The molecular properties have been modulated through introduction of various substitu-
ents at the C-4 atom of 1,2,3-triazole and their impact on biological activities has been estimated by using 
in silico modelling (Cruciani et al., J Mol Struct Theochem 2000), which will be presented.
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This study was designed to verify the eff ect of multi-targeted tyrosine kinase inhibitors on renal cell 
cancer cells along with subpopulation of cancer stem cells. Cells analyzed covered: Human Kidney Cancer 
Stem Cells (HKCSC) isolated from nephrectomy specimen of papillary and clear cell renal cell carcinoma 
(Celprogen Inc), cell line Caki-1 – derived form human metastasis of clear-cell renal cell carcinoma to the 
skin with wt VHL (von Hippel Lindau) gene (ATCC® HTB-46™), 769-P - primary clear- cell renal cell car-
cinoma with VHL mutation (ATCC® CRL-1933™), 786-0 (TCC® CRL-1932™) - primary clear cell adeno-
carcinoma with VHL mutation, ACHN – papillary renal cancer pleural metastasis with wt VHL, and 
SK-RT-42 – clear cell renal cancer bone metastasis. Cells were primarily cultured in monolayer standard 
2D conditions and in order to mimic in vivo conditions cells were cultured also in 3D conditions and in 
ECM coated plates with laminin, collagen I or poly-D-lysine. Cells were also cultured in hypoxia (1-2% 
oxygen tension) to recapitulate intratumoral conditions. Cells were treated with sunitinib, sorafenib or 
axitinib in 2D and 3D conditions. Cell proliferation and TKI toxicity were evaluated with Alamar Blue and 
MTT assay. Renal cell cancer - cancer stem cells proliferation is inhibited by tyrosine kinase inhibitors. 
Hypoxia reduced proliferation of renal cancer cells - increase of percentage of quiescent cells (Ki67-) and 
cells arrested in S phase is found. Effi  cacy of TKIs is limited by hypoxic conditions and cancer cell cell-cell 
interactions. Hypoxia induces downregulation of expression of eukaryotic translation initiation factor B 
(encoded by EIF4B gene) and dual specifi city mitogen-activated protein kinase 1 (encoded by MAP2K1 
gene). Specifi c response to tyrosine kinase inhibitors (TKIs), including primary resistance was also 
observed. HKCSCs cells cultured in hypoxia develop primary resistance to sorafenib, while HKCSCs cul-
tured in normoxia were resistant to axitinib. Understanding the complex molecular feedback loops 
between cancer cells, cancer stem cells and the tumor microenvironment in 3D culture may promote the 
identifi cation of novel treatment targets in renal cancer.
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